[1] 庄辉. 消除乙型肝炎进展[J]. 临床肝胆病杂志,2024,40(5):857-860. [2] Chen P, Yu C, Ruan B, et al.Prevalence of hepatitis B in insular regions of southeast China: A community-based study[J]. PLoS One, 2013, 8(2): e56444. [3] Wang Y, Shu M, Chen J, et al.Hepatitis B immunization status and risk factors of people aged 1to 69 in Huangpu District, Shanghai, China[J]. Front Public Health, 2023, 11: 1302183. [4] 崔富强,杜娟,方钟燎,等. 成人乙型肝炎疫苗接种专家建议[J]. 中国预防医学杂志,2024,25(7):838-844. [5] 闫永平,张维璐,苏海霞,等. 我国乙型病毒性肝炎防治研究新进展和面临的挑战[J]. 中国热带医学,2019,19(10):916-921. [6] Liu Z, Li M, Hutton DW, et al.Impact of the national hepatitis B immunization program in China: A modeling study[J]. Infect Dis Poverty, 2022, 11(1): 106. [7] 中国国家标准化管理委员会. 献血者健康检查要求GB 18467—2011[S].北京:中国标准出版社,2011. [8] Gao Z, Zhang Y, Shan H, et al.A 30-year systematic review and meta-analysis of hepatitis B virus among blood donors in mainland China: Revealing increase of new threats[J]. Transfusion, 2017, 57(8): 1988-1997. [9] Mengjiao L, Yushan X, Yan L, et al.Prevalence of transfusion-transmitted infections in hospitalized patients before transfusion and volunteer blood donors in Zhejiang Province, China[J]. Infect Dis Now, 2024, 54(2): 104861. [10] Guo K, Song S, Qiu L, et al.Prediction of red blood cell demanD for pediatric patients using a time-series model: A single-center study in China[J]. Front Med (Lausanne), 2022, 9: 706284. [11] Schaffer AL, Dobbins TA, Pearson SA.Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: A guide for evaluating large-scale health interventions[J]. BMC Med Res Methodol, 2021, 21(1): 58. [12] 王富珍,郑徽,孙校金,等. 中国控制乙型病毒性肝炎的成就与展望[J]. 中国疫苗和免疫,2019,25(5):487-492. [13] Fu MX, Faddy HM, Candotti D, et al.International review of blood donation screening for anti-HBC and occult hepatitis B virus infection[J]. Transfusion, 2024, 64(11): 2144-2156. [14] Zheng H, Wang Y, Wang FZ, et al.New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. [15] Liu Z, Lin C, Mao X, et al.Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: A systematic literature review and meta-analysis of 3 740 studies and 231 million people[J]. Gut, 2023, 72(12): 2354-2363. [16] 杨波,朱丽莉,于志强,等. 169 897份首次献血者标本HBV检测结果及人口学特征分析[J]. 中国输血杂志,2023,36(11):1019-1022. [17] 冯涛,朱瑞,周春,等. 2016—2020年南京市无偿献血人群HIV/HBV/HCV/TP血清流行病学调查[J]. 中国实验血液学杂志,2022,30(5):1572-1576. [18] 谢君谋,梁浩坚,林诗雅,等. 广州市无偿献血人群血液检测不合格情况回顾及多因素Logistic回归分析[J]. 中国输血杂志,2022,35(8):855-860. [19] Wei L, Chen M, Wang F, et al.Analysis of hepatitis B virus test results among blood donors in Chongqing, China[J]. BMC Infect Dis, 2024, 24(1): 857. [20] Collaborators PO.Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8(10): 879-907. [21] 邓雯,蒋婷婷,王诗雨,等. 乙型肝炎病毒母婴阻断策略[J]. 病毒学报,2023,39(5):1405-1413. [22] 董哲,李雪梅,赵智娴,等. 不同种族/民族乙型肝炎分子流行病学研究进展[J]. 中国公共卫生,2020,36(4):650-653. [23] Su QD, Zhang S, Wang F, et al.Epidemiological distribution of hepatitis B virus genotypes in 1-29-year-olds in the mainland of China[J]. Vaccine, 2020, 38(51): 8238-8246. [24] Dong Z, Li JR, Zhao ZX, et al.Molecular epidemiology of hepatitis B virus genotypes and subgenotypes in ethnic minority populations, Yunnan Province, China[J]. Epidemiol Infect, 2021, 150: e11. |